Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
MBX Biosciences’ $187.7 Million IPO
Generate:Biomedicines’ $273 Million Series C Funding Round
Goodwin advised Generate:Biomedicines on the fundraising. Generate:Biomedicines announced that it has raised $273 million in Series C financing. This financing round attracted many new investors including...
HIBio’s License Agreements with MorphoSys AG
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
Collegium Pharmaceutical’s Acquisition of BioDelivery Sciences International
Goodwin Procter advised BioDelivery Sciences International on the deal while Troutman Pepper advised Collegium Pharmaceutical. BioDelivery Sciences International (NASDAQ: BDSI) announced its definitive merger agreement to be...
Generate Biomedicines’ Research Collaboration Agreement with Amgen
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
G Squared Ascend I’s Business Combination Agreement with Transfix
Goodwin Procter advised G Squared Ascend I on the deal. Latham & Watkins represented Transfix. G Squared Ascend I (NYSE: GSQD), a special purpose acquisition company...
Laronde’s $440 Million Series B Financing
Goodwin Procter advised Laronde on the deal. Laronde announced its $440 million Series B Financing to advance the development of its eRNA platform and a broad pipeline...